Zobrazeno 1 - 10
of 532
pro vyhledávání: '"targeted agent"'
Autor:
Kyoko Oura, Asahiro Morishita, Kei Takuma, Mai Nakahara, Tomoko Tadokoro, Koji Fujita, Shima Mimura, Joji Tani, Masafumi Ono, Takashi Himoto, Tsutomu Masaki
Publikováno v:
Cancer Medicine, Vol 12, Iss 24, Pp 22023-22037 (2023)
Abstract Aim Indications of drug therapies to elderly patients with hepatocellular carcinoma (HCC) should be carefully determined. The current study assessed the safety and efficacy of molecular targeted agents (MTAs) in the elderly patients with HCC
Externí odkaz:
https://doaj.org/article/1f9fc393f2c049ff98af5d20111cb879
Publikováno v:
Cancer Medicine, Vol 12, Iss 22, Pp 21022-21031 (2023)
Abstract Background Rising costs of cancer treatments challenge even areas with universal health coverage. There's a need to assess current medical care utilization trends among patients with cancer to guide public health policy, resource allocation,
Externí odkaz:
https://doaj.org/article/7f316edff1dc4917b8e5787f65433793
Autor:
Alicia K. Morgans, Thomas Hutson, Alice Kai Dan Guan, David Garcia, Anna Zhou, Edward Drea, Nicholas J. Vogelzang
Publikováno v:
BMC Health Services Research, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Cabazitaxel significantly improves clinical outcomes compared with a second androgen receptor-targeted agent (ARTA) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and an
Externí odkaz:
https://doaj.org/article/6d4b407f4b4b48b78c689dd2fe67da45
Autor:
Fucun Xie, Bowen Chen, Xu Yang, Huaiyuan Wang, Ge Zhang, Yanyu Wang, Yunchao Wang, Nan Zhang, Jingnan Xue, Junyu Long, Yiran Li, Huishan Sun, Ziyu Xun, Kai Liu, Xiangqi Chen, Yang Song, Xiaobo Yang, Zhenhui Lu, Yilei Mao, Xinting Sang, Yinying Lu, Haitao Zhao
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundLenvatinib is a standard first-line systemic therapy in advanced hepatocellular carcinoma (aHCC) and is widely used in all lines. However, the efficacy and safety of immune checkpoint inhibitors (ICIs) plus molecular targeted agents (MTAs)
Externí odkaz:
https://doaj.org/article/fb348bd807e94787ae9b086c23530270
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Keita Nakane, Hiromitsu Watanabe, Taku Naiki, Kiyoshi Takahara, Takahiro Yasui, Hideaki Miyake, Ryoichi Shiroki, Takuya Koie
Publikováno v:
Diagnostics, Vol 13, Iss 9, p 1661 (2023)
The advent of second-generation androgen receptor axis-targeted agents (ARATs) has revolutionized the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). Biochemical recurrence-free survival (BRFS) was used to compare the efficacy of e
Externí odkaz:
https://doaj.org/article/f9dc97b7fae64473ba5b8bf91c56a07d
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
The introduction of various targeted agents into the armamentarium of cancer treatment has revolutionized the standard care of patients with cancer. However, like conventional chemotherapy, drug resistance, either preexisting (primary or intrinsic re
Externí odkaz:
https://doaj.org/article/c9c154360eba46e4a04646d30f938fe8
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
The mainstay of medical treatment has been tyrosine kinase inhibitors (TKIs) for renal cell cancer (RCC), cytotoxic chemotherapy for urothelial cancer (UC), and androgen deprivation therapy for prostate cancer. These therapeutic modalities still play
Externí odkaz:
https://doaj.org/article/181c46d569c5411f8f5782c54f224e96
Autor:
Vanina E. Wainsztein, Tom W. Chen
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 69-82 (2020)
Soft tissue sarcomas (STS) account for less than 1% of adult cancers with a median overall survival of 12 months in the metastatic setting. Although chemotherapy remains the standard of treatment for advanced disease, molecular targeted agents (MTAs)
Externí odkaz:
https://doaj.org/article/2bea153e6cbd41bebb635058663ccb15
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.